Related Experiment Video
Updated: Jun 8, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Triptans: where things stand
Alan K Cole1, Michael J Marmura
1Thomas Jefferson University, 111 South 11th Street, Suite 8130, Philadelphia, PA, 19107, USA.
Opinion Statement:
Triptans, selective serotonin receptor agonists, were developed almost 20 years ago and represented a major breakthrough in the treatment of acute migraine attacks. Since then, the triptans have become first-line agents for most patients with migraine, both with and without aura, unless contraindicated. This article reviews the development of triptans, discusses reasons for their success or failure, and examines the limitations and controversies surrounding this class of medication.
Related Concept Videos
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Cholinergic Antagonists: Pharmacokinetics
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...
